Article content

TORONTO — Jack Nathan Medical Corp. (TSXV: JNH, OTCQB: JNHMF) (“Jack Nathan Health”, “JNH” or the “Company”) announced today its unaudited interim consolidated financial results for the third quarter of fiscal 2023. Jack Nathan Health’s financial statements are prepared in accordance with International Financial Reporting Standards (“IFRS”).

Article content

Article content

Management Commentary

Commenting on the Company’s performance and outlook, Dr. Glenn Copeland, Chief Executive Officer and Chief Medical Officer, stated: “Clinic revenues have been on a steady rise over the past few months and with the grand opening of our Hillside location we expect this growth to continue as clinics begin operating to capacity. These positive results are indicative of the strong work of our current management team.”

Spence Walker, CFO, added: “The Company’s focus on reassessing and controlling its operating costs over the past few months has resulted in a reduction of its operating losses, as evidenced by the reduced quarterly operational loss from Q2 to Q3 ($1.5m to $0.9m). As we continue ramping up operations at the newly developed clinics, including Hillside, Victoria which recently had its grand opening, we expect to carry on these economies of scale forward.”

Financial Highlights for the Three and Nine Months Ended October 31, 2022

Operating Results

Note: Please see Management Discussion and Analysis for the nine months ended October 31, 2022, for the detailed breakdown and commentary on Adjusted EBITDA⁽¹⁾.

For the nine months ended October 31, 2022, total revenues were $11,802,010 (2021 – $5,621,042), an increase of $6,180,968 or 110%. The Company continues its growth in revenues driven from its new clinic operations.

Clinic operations revenues of $9,359,758 accounted for 79% of total revenues for the nine months ended October 31, 2022, compared to $2,344,878 or 42% of revenues for the nine months ended October 31, 2021. The significant growth in clinic operations during the nine months ended October 31, 2022, compared to the same period last year, was driven by clinic operations acquisitions made in the second half of fiscal 2022 in Canada. Clinic operations revenues increased significantly due to new program development, acquisitions, as well as reduced COVID 19 restrictions which impacted revenues last year. As of October 31, 2022, in Canada, the Company has 76 clinics in Walmart locations in British Columbia, Alberta, Saskatchewan, Manitoba, Ontario and Quebec, and 4 clinics outside Walmart. 18 medical clinics, 4 Rehab and 5 MedSpa are corporate owned and operated and 62 clinic locations are currently licensed to primarily medical as well as dental, rehab, telemedicine, and imaging licensees. In Mexico, the Company has 114 corporate owned and operated clinics in Walmart locations. including servicing Walmart associates at three clinics inside Walmart’s Distribution Centres. The increase in clinic operations is aligned with the Company’s strategic plan of expanding corporate-owned and operated medical centres with strategic partner Walmart.

Article content

For the nine months ended October 31, 2022, total operating expenses were $15,239,422 (October 31, 2021 – $11,158,763) in Q3 fiscal 2022. The Q3 quarter-over-quarter operating expenses of $5,139,163 (2021 – $4,483,043) were driven by the growth in Clinic Operation revenues of $4.2m noted above, that resulted in increases in several new expenses related to clinic operations including higher associate fees for new medical services, higher clinic operation costs, higher salaries and wages and professional fees, new acquisition related costs and an increase in non-cash charges depreciation and amortization. The operational increases are primarily attributable to the rapid expansion of medical clinics, medical and paramedical practitioners added, and new Rehab and MedSpa services provided.

For the nine months ended October 31, 2022, the Company reported a loss from operations of $3,437,412 (October 31, 2021 – $5,537,721), a decrease of $2,100,309. The overall decrease in Q3 loss from operations is attributable to the specific reductions in consulting expenses and development costs while variable operating expenses increased as they relate to a large growth in clinic revenues.

Balance Sheet as of October 31, 2022

Shares Outstanding

As of December 22, 2022, the Company had 84,329,547 common shares outstanding, 6,675,000 stock options outstanding, 397,604 warrants outstanding, 3,250,000 RSUs outstanding and 502,506 DSUs outstanding.

For further information regarding the Company’s financial results for Q3 fiscal 2023, please refer to the unaudited interim consolidated financial statements as at and for the 3 and 9 months ended October 31, 2022 together with corresponding MD&A, available at www.sedar.com and the JNH website https://www.jacknathanhealth.com.

About Jack Nathan Medical Corp.

Jack Nathan Medical Corp., operating as Jack Nathan Health^®, is one of Canada’s largest healthcare networks. Jack Nathan Health® is an innovative healthcare company that is improving access for millions of patients by co-locating physician and ancillary medical services conveniently located inside Walmart^® stores.

Jack Nathan Health^® provides an exceptional level of patient care, made possible through patient-centric physicians, a variety of medical services, technology, and programs, designed to put patients first. Our mission is to provide everyone access to the finest quality retail medical centres, with both in-clinic physicians and digital telemedicine, so you and your loved ones can “Live Your Best Life”.

Article content

Jack Nathan Health^® was established in 2006 and continues to expand its international footprint, delivering exceptional, state-of-the-art, turn-key medical centres. In Canada, the Company has 76 clinics in Walmart locations in British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, and Quebec. 18 clinics, 4 Rehab and 5 MedSpa are corporate owned and operated. In Mexico, the Company has 108 corporate owned and operated clinics in Walmart locations.

For more information, visit www.jacknathanhealth.com or www.sedar.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Notes:

Certain statements contained in this press release constitute “forward-looking information” as such term is defined in applicable Canadian securities legislation. The words “may,” “would,” “could,” “should,” “potential,” “will,” “seek,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” and similar expressions as they relate to Jack Nathan are intended to identify forward-looking information. All statements other than statements of historical fact may be forward-looking information. Such statements reflect the Company’s current views and intentions with respect to future events, and current information available to them, and are subject to certain risks, uncertainties, and assumptions Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize. Such factors include but are not limited to: changes in economic conditions or financial markets; increases in costs; litigation; legislative and other judicial, regulatory, political, and competitive developments; the economic and business impact of COVID-19 and operational difficulties. This list is not exhaustive of the factors that may affect forward-looking information. These and other factors should be considered carefully, and readers should not place undue reliance on such forward-looking information. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward- looking information, other than as required by applicable law.

Article content

⁽¹⁾ Adjusted EBITDA

We believe Adjusted EBITDA is a useful measure to assess the ongoing performance of our Company as it provides more meaningful operating results by excluding the effects of expenses that are not reflective of our underlying business performance as well as one-time or non-recurring expenses. We define Adjusted EBITDA as EBITDA adjusted to add back or deduct, as applicable, certain expenses, costs, charges, or benefits incurred in the period, which in management’s view, are not indicative of normal operations, including: (i) non-capitalized development costs, (ii) acquisition related costs, (iii) share compensation expense, (iv) bad debt expense(recovery), (v) finance costs (income), and (vi) foreign exchange gain or loss

Non-GAAP measure: Earnings before interest, taxes, depreciation, and amortization (“EBITDA”) and Adjusted EBITDA should not be construed as alternatives to net income (loss) determined in accordance with IFRS. EBITDA and Adjusted EBITDA do not have any standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other issuers. Adjusted EBITDA is a meaningful financial metric as it measures cash generated from operations which the Company can use to fund working capital requirements, service future interest and principal debt repayments and fund future growth initiatives.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221222005516/en/

Contacts

Jack Nathan Medical Corp., Michael Marchelletta, Vice Chairman of the Board of Directors, mike@jacknathanhealth.com, 416-637-2240

#distro